Comparative Pharmacology
Head-to-head clinical analysis: PEDIATRIC ADVIL versus XIBROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIATRIC ADVIL versus XIBROM.
PEDIATRIC ADVIL vs XIBROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
XIBROM (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation.
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
Instill 1 drop into the affected eye(s) 4 times daily starting 24 hours before surgery and continuing for 2 weeks postoperatively.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in children. Clinical context: rapid clearance; requires frequent dosing every 6-8 hours for sustained antipyretic/analgesic effect.
Terminal elimination half-life is approximately 42 hours. Clinical context: Due to its long half-life, steady-state is achieved after about 8 days of daily dosing, which contributes to sustained anti-inflammatory effect.
Renal excretion of conjugated metabolites (glucuronides and sulfates) accounts for >90% of an administered dose, with <1% excreted unchanged. Biliary/fecal elimination is minimal (<5%).
Renal: ~70% (primarily as unchanged drug); Biliary/Fecal: ~15% (as metabolites); the remainder is eliminated via other minor pathways.
Category C
Category C
NSAID
NSAID